Alfredo Ramirez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9570949/publications.pdf

Version: 2024-02-01

192 papers	22,265 citations	32410 55 h-index	12638 137 g-index
221 all docs	221 docs citations	221 times ranked	33715 citing authors

#	Article	IF	Citations
1	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 2023, 19, 487-497.	0.4	25
2	Hypermethylation of the oxytocin receptor gene (OXTR) in obsessive-compulsive disorder: further evidence for a biomarker of disease and treatment response. Epigenetics, 2022, 17, 642-652.	1.3	17
3	Amyloid pathology but notAPOEÎµ4 status is permissive for tau-related hippocampal dysfunction. Brain, 2022, 145, 1473-1485.	3.7	17
4	Association between 9p21-23 Locus and Frailty in a Community-Dwelling Greek Population: Results from the Hellenic Longitudinal Investigation of Ageing and Diet. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-9.	1.5	2
5	Measuring Psychological Mechanisms in Meditation Practice: Using a Phenomenologically Grounded Classification System to Develop Theory-Based Composite Scores. Mindfulness, 2022, 13, 600.	1.6	9
6	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimerâ€™s disease. Neuron, 2022, 110, 1009-1022.e4.	3.8	27
7	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimerâ€™s type. Brain, 2022, 145, 2507-2517.	3.7	16
8	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. Alzheimer's Research and Therapy, 2022, 14, 22.	3.0	5
9	Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimerâ€™s Disease Spectrum. Journal of Alzheimer's Disease, 2022, 85, 1267-1282.	1.2	12
10	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	1.2	5
11	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
12	Vascular burden and genetic risk in association with cognitive performance and dementia in a population-based study. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100145.	0.4	0
13	Alzheimerâ€™s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders, 2022, 51, 182-192.	0.7	16
14	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
15	Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. Cancers, 2022, 14, 3363.	1.7	2
16	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	1.4	46
17	Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimerâ€™s disease. European Journal of Nutrition, 2021, 60, 849-860.	1.8	31
18	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	4.1	61

#	Article	IF	Citations
19	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. Journal of Alzheimer's Disease, 2021, 79, 493-509.	1.2	14
20	Multiomics integrative analysis identifies APOE allele-specific blood biomarkers associated to Alzheimerâ€™s disease etiopathogenesis. Aging, 2021, 13, 9277-9329.	1.4	15
21	Generation of a set of isogenic iPSC lines carrying all APOE genetic variants (Æ2/Æ3/Æ4) and knock-out for the study of APOE biology in health and disease. Stem Cell Research, 2021, 52, 102180.	0.3	1
22	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.5	72
23	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
24	Resting-State Network Alterations Differ between Alzheimerâ€™s Disease Atrophy Subtypes. Cerebral Cortex, 2021, 31, 4901-4915.	1.6	12
25	Mapping the human genetic architecture of COVID-19. Nature, 2021, 600, 472-477.	13.7	640
26	Polygenic risk for obsessive-compulsive disorder (OCD) predicts brain response during working memory task in OCD, unaffected relatives, and healthy controls. Scientific Reports, 2021, 11, 18914.	1.6	8
27	TH56. HYPERMETHYLATION OF THE OXYTOCIN RECEPTOR GENE IN OBSESSIVE-COMPULSIVE DISORDER: FURTHER EVIDENCE FOR A BIOMARKER OF DISEASE AND TREATMENT RESPONSE. European Neuropsychopharmacology, 2021, 51, e224.	0.3	1
28	Eicosapentaenoic Acid Is Associated with Decreased Incidence of Alzheimerâ€™s Dementia in the Oldest Old. Nutrients, 2021, 13, 461.	1.7	18
29	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12223.	1.2	4
30	APOE É›4 Is Associated with Postprandial Inflammation in Older Adults with Metabolic Syndrome Traits. Nutrients, 2021, 13, 3924.	1.7	4
31	Association of the Polygenic Risk Score With the Probability of Prodromal Parkinsonâ€™s Disease in Older Adults. Frontiers in Molecular Neuroscience, 2021, 14, 739571.	1.4	6
32	Individualized MRâ€based prediction of cognitive performance in subjects at risk of dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
33	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
34	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
35	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055982.	0.4	1
36	Correlates of hospitalization among the oldest old: results of the AgeCoDeâ€“AgeQualiDe prospective cohort study. Aging Clinical and Experimental Research, 2020, 32, 1295-1301.	1.4	14

#	Article	IF	Citations
37	A rare heterozygous TREM2 coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. Human Mutation, 2020, 41, 169-181.	1.1	4
38	The association between genomeâ€wide polymorphisms and chronic postoperative pain: a prospective observational study. Anaesthesia, 2020, 75, e111-e120.	1.8	11
39	Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 124.	3.0	12
40	The polygenic risk for obsessiveâ€compulsive disorder is associated with the personality trait harm avoidance. Acta Psychiatrica Scandinavica, 2020, 142, 326-336.	2.2	13
41	Intermediate phenotype of ATP13A2 mutation in two Chilean siblings: Towards a continuum between parkinsonism and hereditary spastic paraplegia. Parkinsonism and Related Disorders, 2020, 81, 45-47.	1.1	4
42	Worldwide surveillance of self-reported sitting time: a scoping review. International Journal of Behavioral Nutrition and Physical Activity, 2020, 17, 111.	2.0	52
43	Potential epigenetic pathways linking high mental work demands to dementia risk. Alzheimer's and Dementia, 2020, 16, e039663.	0.4	0
44	Can OMICS data help us to understand the mechanisms of APOE?. Alzheimer's and Dementia, 2020, 16, e040276.	0.4	0
45	Crossâ€omics studies of the role of apolipoprotein E in Alzheimerâ€™s disease and dementia: Searching common pathways in patients, populations and cellular models. Alzheimer's and Dementia, 2020, 16, e040282.	0.4	0
46	APOE and sexâ€stratified genomeâ€wide metaâ€analyses of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e040779.	0.4	2
47	Exome sequencing identifies three novel ADâ€associated genes. Alzheimer's and Dementia, 2020, 16, e041592.	0.4	6
48	Intrathecal antibodies against herpes simplex virus are associated with tau pathology in humans with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041938.	0.4	1
49	Development of a fast and versatile method for genomeâ€wide association studies of longitudinal data. Alzheimer's and Dementia, 2020, 16, e042441.	0.4	0
50	Lifestyle differences modulate the effects of cognitive reserve on functional connectivity. Alzheimer's and Dementia, 2020, 16, e042947.	0.4	0
51	Hippocampal volumetric variability is associated with memory in subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e043527.	0.4	0
52	Genomeâ€wide metaâ€analysis of lateâ€onset Alzheimerâ€™s disease using rare variant imputation in 65,602 subjects identifies risk loci with roles in memory, neurodevelopment, and cardiometabolic traits: The international genomics of Alzheimerâ€™s project (IGAP). Alzheimer's and Dementia, 2020, 16, e044193.	0.4	1
53	SORL1 â€variant carriers in ADESâ€ADSP: A higher level of variant pathogenicity associates with earlier age at onset of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044492.	0.4	1
54	Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease. Redox Biology, 2020, 34, 101546.	3.9	66

#	Article	IF	Citations
55	CDH6 and HAGH protein levels in plasma associate with Alzheimerâ€™s disease in APOE Îµ4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
56	Association of a CAMK2A genetic variant with logical memory performance and hippocampal volume in the elderly. Brain Research Bulletin, 2020, 161, 13-20.	1.4	3
57	Neuroimmune Connections in Aging and Neurodegenerative Diseases. Trends in Immunology, 2020, 41, 300-312.	2.9	111
58	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	3.9	40
59	Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, e1134-e1143.	1.5	58
60	SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-3.	1.5	3
61	Amyloid-related changes of basal forebrain volume and precuneus functional connectivity in Subjective Cognitive Decline patients. , 2020, 59, .		0
62	Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimer's Research and Therapy, 2019, 11, 66.	3.0	74
63	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218111.	1.1	23
64	Does transpersonal trust moderate the association between chronic conditions and general practitioner visits in the oldest old? Results of the AgeCoDe and AgeQualiDe study. Geriatrics and Gerontology International, 2019, 19, 705-710.	0.7	5
65	T40. Alzheimerâ€™s Disease DNA (Hydroxy)Methylome in the Brain and Blood: Evidence for OXT Methylation as a Preclinical Marker. Biological Psychiatry, 2019, 85, S144.	0.7	1
66	M62 THE POLYGENIC RISK FOR OBSESSIVE-COMPULSIVE DISORDER IS ASSOCIATED WITH HARM AVOIDANCE IN A SAMPLE OF OCD PATIENTS, UNAFFECTED RELATIVES AND CONTROLS. European Neuropsychopharmacology, 2019, 29, S199-S200.	0.3	0
67	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimerâ€™s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465.	1.2	15
68	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 55.	2.4	32
69	Generation of a set of isogenic, gene-edited iPSC lines homozygous for all main APOE variants and an APOE knock-out line. Stem Cell Research, 2019, 34, 101349.	0.3	29
70	Prevalence of Anxiety Symptoms and Their Association With Loss Experience in a Large Cohort Sample of the Oldest-Old. Results of the AgeCoDe/AgeQualiDe Study. Frontiers in Psychiatry, 2019, 10, 285.	1.3	22
71	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
72	GBA and APOE Îµ4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	1.6	53

#	Article	IF	Citations
73	Reply: Biallelic POLR3A variants confirmed as a frequent cause of hereditary ataxia and spastic paraparesis. Brain, 2019, 142, e13-e13.	3.7	4
74	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates Aî², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
75	THE APOE-îµ4 ALLELE AND AGE SYNERGISTICALLY DRIVE DISEASE PROGRESSION IN ALZHEIMERâ€™S DISEASE. Innovation in Aging, 2019, 3, S943-S943.	0.0	0
76	Alzheimerâ€™s disease-associated (hydroxy)methylomic changes in the brain and blood. Clinical Epigenetics, 2019, 11, 164.	1.8	88
77	Cognitive behavioural therapy for the treatment of late life depression: study protocol of a multicentre, randomized, observer-blinded, controlled trial (CBTlate). BMC Psychiatry, 2019, 19, 423.	1.1	11
78	Methylomic profiling in trisomy 21 identifies cognition- and Alzheimerâ€™s disease-related dysregulation. Clinical Epigenetics, 2019, 11, 195.	1.8	14
79	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	3.7	83
80	Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nature Genetics, 2018, 50, 381-389.	9.4	1,332
81	Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. , 2018, 14, 848-857.		36
82	Genetic estimators of DNA methylation provide insights into the molecular basis of polygenic traits. Translational Psychiatry, 2018, 8, 31.	2.4	12
83	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimerâ€™s disease (DELCODE). Alzheimer's Research and Therapy, 2018, 10, 15.	3.0	131
84	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. Alzheimer's and Dementia, 2018, 14, 707-722.	0.4	143
85	Reply: POLR3A variants in hereditary spastic paraplegia and ataxia. Brain, 2018, 141, e2-e2.	3.7	10
86	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
87	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. Alzheimer's and Dementia, 2018, 14, P276.	0.4	0
88	O5â€04â€01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.4	0
89	P1â€140: A GENERIC LATENT VARIABLE APPROACH FOR MEASURING COGNITIVE RESERVE: PHENOTYPE VALIDATION AND GENETIC ASSOCIATION RESULTS. Alzheimer's and Dementia, 2018, 14, P328.	0.4	0
90	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. Alzheimer's and Dementia, 2018, 14, P1352.	0.4	8

#	Article	IF	Citations
91	P3â€122: APOEâ€Îµ4 MODULATES LEVELS OF OMEGAâ€3 AND OMEGAâ€6 FATTY ACIDS IN ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1114.	0.4	0
92	Genome-wide significant risk factors on chromosome 19 and the APOE locus. Oncotarget, 2018, 9, 24590-24600.	0.8	22
93	The SCDâ€Well randomized controlled trial: Effects of a mindfulnessâ€based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 737-745.	1.8	26
94	P1â€298: CEREBROSPINAL FLUID AND PLASMA LEVELS OF LYSOPHOSPHATIDIC ACIDS (LPAS) ASSOCIATE WITH CEREBROSPINAL FLUID AÎ²â€42 AND Pâ€TAU. Alzheimer's and Dementia, 2018, 14, P403.	0.4	0
95	P3â€131: LOOKING FOR THERAPEUTIC ENTRY POINTS FOR ALZHEIMER'S DISEASE: LESSONS LEARNED FROM AGNOSTIC TRANSâ€COâ€REGULATORY NETWORK ANALYSES OF APOE, TREM2, PLCG2 AND ABI3 LOCI. Alzheimer's and Dementia, 2018, 14, P1117.	0.4	0
96	P2â€431: RELATIONSHIP BETWEEN LOCAL RESTING STATE ACTIVITY, Î²â€AMYLOID DEPOSITION AND MEMORY PERFORMANCE IN THE DZNE: LONGITUDINAL COGNITIVE IMPAIRMENT AND DEMENTIA STUDY (DELCODE). Alzheimer's and Dementia, 2018, 14, P877.	0.4	0
97	3 .Neuropathologie und molekulare Mechanismen. , 2018, , 35-122.		1
98	Exploring Genetic Associations of Alzheimerâ€™s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes. Frontiers in Aging Neuroscience, 2018, 10, 340.	1.7	12
99	Genetically elevated highâ€density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 595-598.	1.2	2
100	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	1.2	26
101	P1â€159: RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?. Alzheimer's and Dementia, 2018, 14, P337.	0.4	0
102	Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications, 2018, 9, 2098.	5.8	484
103	Blood-derived integration-free iPS cell line UKBi011-A from a diagnosed male Alzheimer's disease patient with APOE É›4/É›4 genotype. Stem Cell Research, 2018, 29, 250-253.	0.3	5
104	Genome-wide significant risk factors for Alzheimerâ€™s disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. Molecular Psychiatry, 2017, 22, 153-160.	4.1	102
105	Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia. Brain, 2017, 140, 1561-1578.	3.7	85
106	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
107	Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer. JAMA Oncology, 2017, 3, 1245.	3.4	74
108	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783

#	Article	IF	Citations
109	[P2â€“550]: CONNECTIVITY OF THE LEFT FRONTAL CORTEX ATTENUATES DETRIMENTAL EFFECTS OF CSFâ€tTAU ON MEMORY IN PRECLINICAL AND CLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P854.	0.4	0
110	[P3â€“164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE CÎ³2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P997.	0.4	0
111	[P3â€“528]: PROSPECTIVE ASSOCIATIONS BETWEEN VITAMINS, METABOLITES, AND OVERALL DEMENTIA IN THE OLDESTâ€OLD. Alzheimer's and Dementia, 2017, 13, P1180.	0.4	2
112	[P1â€“139]: PATHWAYâ€SPECIFIC GENETIC RISK SCORE ASSOCIATED WITH ALZHEIMER's DISEASE AND WHITE MATTER LESIONS IN COGNITIVELY NORMAL SUBJECTS. Alzheimer's and Dementia, 2017, 13, P295.	0.4	0
113	[P1â€“340]: CASE REPORT: HETEROZYGOUS APP A713T MUTATION CARRIER WITH INFLAMMATORY AMYLOID ANGIOPATHY AND FAMILY HISTORY OF AD: FIRST CASE IN ARGENTINA. Alzheimer's and Dementia, 2017, 13, P386.	0.4	0
114	[P1â€“554]: OPTIMAL HARMONIZATION OF COGNITIVE MEASURES ENHANCES THE DETECTION OF GENETIC EFFECTS ON ALZHEIMER's DISEASE PROGRESSION: A COMPARISON OF SIX STATISTICAL APPROACHES IN 1796 MCI PATIENTS FROM THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P506.	0.4	0
115	Caspase-8, association with Alzheimerâ€™s Disease and functional analysis of rare variants. PLoS ONE, 2017, 12, e0185777.	1.1	38
116	Apolipoprotein E Îµ4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	1.1	22
117	No association of the variant rs11887120 in DNMT3A with cognitive decline in individuals with mild cognitive impairment. Epigenomics, 2016, 8, 593-598.	1.0	5
118	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	2.8	56
119	TREM2 rare variant p.R47H is not associated with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 23, 109-111.	1.1	17
120	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Alzheimer's and Dementia, 2016, 12, 872-881.	0.4	50
121	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2016, 39, 709-716.	4.3	55
122	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
123	P2-049: Functional characterization of a novel TREM2 coding variant linked to familial Alzheimer's disease. , 2015, 11, P500-P500.		2
124	Elevated HbA1c is Associated with Increased Risk of Incident Dementia in Primary Care Patients. Journal of Alzheimer's Disease, 2015, 44, 1203-1212.	1.2	52
125	MAPT H1 Haplotype is Associated with Late-Onset Alzheimerâ€™s Disease Risk in APOE É›4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. Journal of Alzheimer's Disease, 2015, 49, 343-352.	1.2	32
126	Low High-Density Lipoprotein and Risk of Myocardial Infarction. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S26624.	0.6	19

#	Article	IF	Citations
127	Populationâ€«scp›B‹/scp›ased ‹scp›G‹/scp›enetic ‹scp›S‹/scp›tudies: ‹scp›T‹/scp›he ‹scp›S‹/scp›earch for ‹scp›C‹/scp›ausative ‹scp›V‹/scp›ariants in ‹scp›P‹/scp›arkinson's ‹scp›D‹/scp›isease. Movement Disorders, 2015, 30, 1297-1300.	2.2	0
128	Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLoS Medicine, 2015, 12, e1001841.	3.9	153
129	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	1.5	27
130	Novel genetic matching methods for handling population stratification in genome-wide association studies. BMC Bioinformatics, 2015, 16, 84.	1.2	8
131	Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins. Cell Reports, 2015, 11, 1134-1146.	2.9	88
132	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	13.7	58
133	Common polygenic variation enhances risk prediction for Alzheimerâ€™s disease. Brain, 2015, 138, 3673-3684.	3.7	359
134	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
135	The rare ‹i›TREM2‹/i› R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology, 2014, 83, 1353-1358.	1.5	40
136	SUCLG2 identified as both a determinator of CSF AÎ²1â€“42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	1.4	45
137	Follow-up of loci from the International Genomics of Alzheimerâ€™s Disease Project identifies TRIP4 as a novel susceptibility gene. Translational Psychiatry, 2014, 4, e358-e358.	2.4	98
138	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	3.9	75
139	Rare Variant Testing of Imputed Data: An Analysis Pipeline Typified. Human Heredity, 2014, 78, 164-178.	0.4	3
140	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600
141	DNA Methylation of the TNF-Î± Promoter Region in Peripheral Blood Monocytes and the Cortex of Human Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders, 2014, 38, 10-15.	0.7	27
142	Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation. Journal of Neurology, 2014, 261, 207-212.	1.8	40
143	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	1.5	34
144	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93

#	Article	IF	Citations
145	Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S269-76.	0.4	47
146	O4-04-04: TOWARD FINE MAPPING AND FUNCTIONAL CHARACTERIZATION OF GENOME-WIDE ASSOCIATION STUDY-IDENTIFIED LOCUS RS74615166 (TRIP4) FOR ALZHEIMER'S DISEASE. , 2014, 10, P257-P258.		1
147	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
148	Glucocerebrosidase mutations in a <scp>S</scp>erbian <scp>P</scp>arkinson's disease population. European Journal of Neurology, 2013, 20, 402-405.	1.7	53
149	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
150	Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15097-15102.	3.3	50
151	A Panâ€<scp>E</scp>uropean Study of theC9orf72Repeat Associated with<scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	1.1	247
152	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Annals of Neurology, 2013, 73, 537-545.	2.8	128
153	A One-Degree-of-Freedom Test for Supra-Multiplicativity of SNP Effects. PLoS ONE, 2013, 8, e78038.	1.1	2
154	Linking Protective GAB2 Variants, Increased Cortical GAB2 Expression and Decreased Alzheimerâ€™s Disease Pathology. PLoS ONE, 2013, 8, e64802.	1.1	13
155	Frequency of the D620N Mutation in VPS35 in Parkinson Disease. Archives of Neurology, 2012, 69, 1360.	4.9	76
156	Lysosomal dysfunction in Parkinson disease. Autophagy, 2012, 8, 1389-1391.	4.3	69
157	Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9611-9616.	3.3	309
158	ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiology of Aging, 2012, 33, 1843.e1-1843.e7.	1.5	106
159	Motor pathway excitability in ATP13A2 mutation carriers: A transcranial magnetic stimulation study. Parkinsonism and Related Disorders, 2012, 18, 590-594.	1.1	6
160	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	13.9	810
161	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	13.9	1,426
162	Variants in the 3â€²UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. European Journal of Human Genetics, 2012, 20, 1265-1269.	1.4	19

#	Article	IF	Citations
163	Association of Parkinson disease to PARK16 in a Chilean sample. Parkinsonism and Related Disorders, 2011, 17, 70-71.	1.1	19
164	Homozygous THAP1 mutations as cause of earlyâ€onset generalized dystonia. Movement Disorders, 2011, 26, 858-861.	2.2	39
165	An unusual neurological syndrome of crawling gait, dystonia, pyramidal signs, and limited speech. Movement Disorders, 2011, 26, 2279-2283.	2.2	3
166	Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiology of Disease, 2010, 39, 402-408.	2.1	43
167	Clinical spectrum of Kuforâ€Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Movement Disorders, 2010, 25, 1929-1937.	2.2	93
168	Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease. Movement Disorders, 2010, 25, 2665-2669.	2.2	53
169	Eye movement disorders in ATP13A2 mutation carriers (PARK9). Movement Disorders, 2010, 25, 2687-2689.	2.2	14
170	Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts. PLoS ONE, 2010, 5, e12962.	1.1	140
171	Clinical and Genetic Analysis of a Chilean Family with Early-Onset Autosomal Dominant Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 757-761.	1.2	5
172	Nonmotor Symptoms in Genetic Parkinson Disease. Archives of Neurology, 2010, 67, 670-6.	4.9	53
173	Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. Human Molecular Genetics, 2010, 19, 3124-3137.	1.4	117
174	Recessively Inherited Parkinsonism. Archives of Neurology, 2010, 67, 1357-63.	4.9	73
175	A mutation in the signal sequence ofLRP5in a family with an osteoporosis-pseudoglioma syndrome (OPPG)-like phenotype indicates a novel disease mechanism for trinucleotide repeats. Human Mutation, 2009, 30, 641-648.	1.1	27
176	Genetic association study of the Pâ€type ATPase ATP13A2 in lateâ€onset Parkinson's disease. Movement Disorders, 2009, 24, 429-433.	2.2	13
177	ATP13A2 variants in earlyâ€onset Parkinson's disease patients and controls. Movement Disorders, 2009, 24, 2104-2111.	2.2	62
178	CLCN2 variants in idiopathic generalized epilepsy. Nature Genetics, 2009, 41, 954-955.	9.4	50
179	G proteinâ€“coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nature Genetics, 2008, 40, 329-334.	9.4	385
180	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	g	171

#	Article	IF	Citations
181	MigraÃ±a con aura: Una mirada molecular a un problema hereditario. Revista Chilena De Neuro-Psiquiatria, 2006, 44, 98.	0.0	0
182	Multiple isoforms of the tumor protein p73 are expressed in the adult human telencephalon and choroid plexus and present in the cerebrospinal fluid. European Journal of Neuroscience, 2006, 23, 2109-2118.	1.2	28
183	Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genetics, 2006, 38, 1184-1191.	9.4	1,046
184	Rare missense variants inATP1A2 in families with clustering of common forms of migraine. Human Mutation, 2005, 26, 315-321.	1.1	72
185	Identification of a novel mutation in the coding region of the grey-lethal geneOSTM1in human malignant infantile osteopetrosis. Human Mutation, 2004, 23, 471-476.	1.1	69
186	Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nature Genetics, 2003, 33, 527-532.	9.4	297
187	Cloning and Characterization of SLC26A6, a Novel Member of the Solute Carrier 26 Gene Family. Genomics, 2001, 72, 43-50.	1.3	84
188	Mutation of CDH23, encoding a new member of the cadherin gene family, causes Usher syndrome type 1D. Nature Genetics, 2001, 27, 108-112.	9.4	442
189	Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nature Genetics, 2001, 28, 218-219.	9.4	206
190	Characterization of ADAMTS14, a novel member of the ADAMTS metalloproteinase family. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1522, 221-225.	2.4	27
191	Splice variants of a ClC-2 chloride channel with differing functional characteristics. American Journal of Physiology - Cell Physiology, 2000, 279, C1198-C1210.	2.1	58
192	PLCG2 Protective Variant p.P522R Modulates Tau Pathology and Disease Progression in Patients with Mild Cognitive Impairment. SSRN Electronic Journal, 0, , .	0.4	0